Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Twist Bioscience Corporation TWST

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throu...


Recent & Breaking News (NDAQ:TWST)

Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2

Business Wire May 6, 2020

Twist Bioscience to Report Fiscal 2020 Second Quarter Financial Results on Thursday, May 7, 2020

Business Wire April 30, 2020

Twist Bioscience Expands Flexibility of Clonal Genes for Pharmaceutical, Biotechnology and Industrial Chemical Research

Business Wire April 20, 2020

Twist Bioscience Partners with Vanderbilt University Medical Center to Supply Critical Products and Identify Antibody Therapeutics for COVID-19

Business Wire March 26, 2020

Twist Bioscience Synthetic SARS-CoV-2 RNA Controls Added to FDA Website as Reference Materials

Business Wire March 25, 2020

Twist Announces Availability of Next-Generation Sequencing Target Enrichment Panel for SARS-CoV-2/COVID-19 Research

Business Wire March 16, 2020

Twist Bioscience Announces Availability of Synthetic SARS-CoV-2 RNA Controls

Business Wire March 12, 2020

Twist Bioscience and SOPHiA GENETICS Collaborate to Offer Optimized Genomic Solutions

Business Wire February 26, 2020

Twist Bioscience to Present at the Cowen 40th Annual Health Care Conference

Business Wire February 26, 2020

Twist Bioscience and Miroculus Agree to Collaborate on Next-Generation Sequencing Target Enrichment and Library Preparation Tools for Clinical Research

Business Wire February 25, 2020

Twist Bioscience Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire February 24, 2020

Twist Bioscience Launches New NGS Solutions, Highlights Customers at 2020 Advances in Genome Biology and Technology Conference

Business Wire February 24, 2020

GenapSys Partners With Twist Bioscience to Bring Next-Generation Sequencing Target Enrichment and Library Preparation to World's Most Accessible Highly Accurate Sequencer

Business Wire February 24, 2020

Twist Bioscience Announces Pricing of Upsized $130.0 Million Public Offering of Common Stock

Business Wire February 19, 2020

Twist Bioscience Announces Proposed Public Offering of Common Stock

Business Wire February 18, 2020

Twist Bioscience Now ISO 27001:2013 Certified for Information Security Management System

Business Wire February 12, 2020

Twist Bioscience Reports First Quarter Fiscal 2020 Financial Results

Business Wire February 6, 2020

Twist Bioscience Announces Settlement Agreement with Agilent

Business Wire February 6, 2020

Twist Bioscience Announces Completion of $50 Million Registered Direct Offering Priced At-The-Market

Business Wire January 27, 2020

Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus

PR Newswire January 23, 2020